Design of Antibody−Maytansinoid Conjugates Allows for Efficient Detoxification via Liver Metabolism
- 10 March 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 22 (4), 728-735
- https://doi.org/10.1021/bc100498q
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast CancerJournal of Clinical Oncology, 2010
- Potent antibody drug conjugates for cancer therapyCurrent Opinion in Chemical Biology, 2009
- The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma CellsIn vitroandIn vivoClinical Cancer Research, 2009
- Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's LymphomaClinical Cancer Research, 2009
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug ConjugateCancer Research, 2008
- αv Integrin-Targeted Immunoconjugates Regress Established Human Tumors in Xenograft ModelsClinical Cancer Research, 2007
- Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular ProcessingCancer Research, 2006
- Antibody-Drug Conjugates Designed to Eradicate Tumors with Homogeneous and Heterogeneous Expression of the Target AntigenCancer Research, 2006
- Drug-conjugated monoclonal antibodies for the treatment of cancerCurrent Opinion in Pharmacology, 2005
- Arming antibodies for cancer therapyCurrent Opinion in Pharmacology, 2005